Rebecca Mary Myerson
University of Wisconsin Madison
Department of Population Health Sciences
University of Wisconsin School of Medicine and Pub
610 Walnut Street, 701 WARF
Madison, WI 53703
Institutional Affiliation: University of Wisconsin Madison
Information about this author at RePEc
NBER Working Papers and Publications
|September 2019||Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?|
with Reginald Tucker-Seeley, Dana Goldman, Darius N. Lakdawalla: w26292
Medicare is a large government health insurance program in the United States which covers about 60 million people. This paper analyzes the effects of Medicare insurance on health for a group of people in urgent need of medical care: people with cancer. We used a regression discontinuity design to assess impacts of near-universal Medicare insurance at age 65 on cancer detection and outcomes, using population-based cancer registries and vital statistics data. Our analysis focused on the three tumor sites for which screening is recommended both before and after age 65: breast, colorectal, and lung cancer. At age 65, cancer detection increased by 72 per 100,000 population among women and 33 per 100,000 population among men; cancer mortality also decreased by 9 per 100,000 population for women ...
Published: Rebecca M. Myerson, Reginald D. Tucker‐Seeley, Dana P. Goldman, and Darius N. Lakdawalla “Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?” Journal of Policy Analysis and Management
|February 2018||Effects of Expanding Health Screening on Treatment - What Should We Expect? What Can We Learn?|
with Darius Lakdawalla, Lisandro D. Colantonio, Monika Safford, David Meltzer: w24347
Screening interventions can produce very different treatment outcomes, depending on the reasons why patients had been unscreened in the first place. Economists have paid scant attention to these complexities and their implications for evaluating screening programs. In this paper, we propose a simple economic framework to guide policy-makers and analysts in designing and evaluating the impact of screening on treatment uptake. We apply these insights to several salient empirical examples that illustrate the different kinds of effects screening programs might produce. Our empirical examples focus on contexts relevant to the top cause of death in the United States, heart disease. We find that currently undiagnosed patients differ from currently diagnosed patients in important ways, leading to ...